Anlotinib Completed Phase 2 Trials for Lung Cancer Small Cell Lung Cancer (SCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03059797Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)